---
figid: PMC4403665__nihms663395f1
figtitle: Chemotherapeutic Targeting of the Transforming Growth FactorB Pathway in
  Breast Cancers
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Mouse mammary tumor virus
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC4403665
filename: nihms663395f1.jpg
figlink: /pmc/articles/PMC4403665/figure/F1/
number: F1
caption: TGF-β regulates normal and malignant MEC behavior by binding and activating
  two transmembrane Ser/Thr protein kinase receptors, namely TβR-I and TβR-II, whose
  binding to TGF-β is modulated by TβR-III. Activation of these ligand:receptor ternary
  complexes requires TβR-II to transphosphorylate TβR-I, which subsequently phosphorylates
  and activates Smad2/3. The phosphorylated forms of Smad2/3 form heterocomplexes
  with Smad4, which collectively accumulate in the nucleus to mediate canonical TGF-β
  signaling. Likewise, noncanonical TGF-β signaling transpires via the activation
  of an ever expanding list of downstream effectors, including integrins, FAK and
  Pyk2, MAP kinases, Src, PI3K/AKT/mTOR, NF-κB, and Cox-2. Also shown are various
  anti-TGF-β agents and their molecular targets. See text for additional details.
papertitle: Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway
  in Breast Cancers.
reftext: Yong-Hun Lee, et al. Breast Cancer Manag. 2014;3(1):73-85.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9397165
figid_alias: PMC4403665__F1
figtype: Figure
redirect_from: /figures/PMC4403665__F1
ndex: 1ba41f96-df06-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4403665__nihms663395f1.html
  '@type': Dataset
  description: TGF-β regulates normal and malignant MEC behavior by binding and activating
    two transmembrane Ser/Thr protein kinase receptors, namely TβR-I and TβR-II, whose
    binding to TGF-β is modulated by TβR-III. Activation of these ligand:receptor
    ternary complexes requires TβR-II to transphosphorylate TβR-I, which subsequently
    phosphorylates and activates Smad2/3. The phosphorylated forms of Smad2/3 form
    heterocomplexes with Smad4, which collectively accumulate in the nucleus to mediate
    canonical TGF-β signaling. Likewise, noncanonical TGF-β signaling transpires via
    the activation of an ever expanding list of downstream effectors, including integrins,
    FAK and Pyk2, MAP kinases, Src, PI3K/AKT/mTOR, NF-κB, and Cox-2. Also shown are
    various anti-TGF-β agents and their molecular targets. See text for additional
    details.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LINC01150
  - TGFBR2
  - TGFB1
  - TGFB2
  - TGFB3
  - SMAD3
  - MTOR
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SMAD2
  - SMAD4
  - SGSM3
  - PTK2
  - PTK2B
  - SRC
  - FGR
  - FYN
  - YES1
  - NFKB1
  - PTGS2
  - Tgfbr2
  - Tgfb1
  - Ltbp1
  - Smad3
  - Mtor
  - Akt1
  - Pik3r1
  - Smad2
  - Smad4
  - Ptk2
  - Ptk2b
  - Src
  - Nfkb1
  - Ptgs2
  - Pik3cg
  - dpp
  - gbb
  - put
  - mav
  - Tor
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Smox
  - Med
  - mapP
  - Fak
  - Src42A
  - Csk
  - Src64B
  - Dif
  - dl
  - Rel
  - COX2
  - si:busm1-57f23.1
  - smad3a
  - mtor
  - smad2
  - smad4a
  - smad4b
  - pak2a
  - itpka
  - ptk2ab
  - src
  - SB-431542
  - SB-505124
  - LY364947
  - LY2109761
  - LY2157299
---
